Healthcare -
Medical - Devices - NASDAQ - US
$ 2.95
-3.91 %
$ 374 M
Market Cap
-32.78
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cytek Biosciences, Inc.
| Net Income | -6.02 M |
| Depreciation & Amortization | 10.5 M |
| Capital Expenditures | -3.52 M |
| Stock-Based Compensation | 26.8 M |
| Change in Working Capital | 0 |
| Others | -10.8 M |
| Free Cash Flow | 21.9 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (6.0) | (12.1) | 2.5 | 3.0 | 19.4 | (16.8) |
| Depreciation & Amortization | 10.5 | 9.2 | 5.7 | 1.2 | 0.6 | 0.3 |
| Deferred Income Tax | (2.9) | 0 | 0 | 0.4 | 1.7 | 0 |
| Stock Based Compensation | 26.8 | 22.0 | 16.6 | 6.6 | 0.6 | 0.3 |
| Other Operating Activities | (10.8) | (3.3) | 3.0 | 2.0 | 0.3 | 1.3 |
| Change in Working Capital | 0 | (10.5) | (39.9) | (8.6) | (7.5) | 1.2 |
| Cash From Operations | 25.4 | 5.3 | (12.2) | 4.6 | 15.2 | (13.7) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (3.5) | (4.8) | (9.9) | (4.4) | (1.5) | (1.0) |
| Other Items | (79.4) | (89.1) | (46.0) | (16.6) | 0 | 0 |
| Cash From Investing Activities | (83.0) | (93.9) | (55.9) | (21.0) | (1.5) | (1.0) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | (21.6) | (44.2) | (0.2) | 0 | 0 | 0 |
| Total Debt Repaid | 3.6 | (0.6) | 2.9 | 0 | 2.8 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.2 | 2.9 | 2.6 | 213.6 | 239.5 | 93 K |
| Cash From Financing Activities | (15.8) | (41.8) | 5.5 | 213.6 | 122.6 | 93 K |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (68.9) | (131.9) | (65.1) | 198.5 | 135.6 | (14.7) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | 21.9 | 0.5 | (22.1) | 0.3 | 13.6 | (14.7) |